EBOS GROUP LIMITED (EBO)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

EBO - EBOS GROUP LIMITED

FNArena Sector : Healthcare services
Year End: June
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: 2.25
Index: ASX300 | ALL-ORDS

LAST PRICE CHANGE +/- CHANGE % VOLUME

$31.85

25 Jul
2024

0.220

OPEN

$31.59

0.70%

HIGH

$32.11

89,021

LOW

$31.40

TARGET
$36.38 14.2% upside
Franking for last dividend paid out: 96%
OTHER COMPANIES IN THE SAME SECTOR
ACL . AHX . ALC . BMT . CAJ . DOC . HLS . M7T . MDR . MPL . MVF . NHF . PSQ . RHC . SHL .
FNARENA'S MARKET CONSENSUS FORECASTS
EBO: 1
Title FY22
Actual		 FY23
Actual		 FY24
Forecast		 FY25
Forecast
EPS (cps) xxx 132.9 154.4 xxx
DPS (cps) xxx N/A 105.0 xxx
EPS Growth xxx 16.1% 16.2% xxx
DPS Growth xxx N/A N/A xxx
PE Ratio xxx N/A 20.7 xxx
Dividend Yield xxx N/A 3.3% xxx
Div Pay Ratio(%) xxx N/A 68.0% xxx

Dividend yield today if purchased 3 years ago: 1.72%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 1.60

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages

Last ex-div: 29/02 - ex-div 47.56c (franking 96%)

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2024 FactSet UK Limited. All rights reserved
Title 201820192020202120222023
EPS Basic xxxxxxxxxxxxxxx132.9
DPS All xxxxxxxxxxxxxxx107.9
Sales/Revenue xxxxxxxxxxxxxxx12,237.4 M
Book Value Per Share xxxxxxxxxxxxxxx1,270.5
Net Operating Cash Flow xxxxxxxxxxxxxxx391.4 M
Net Profit Margin xxxxxxxxxxxxxxx2.07 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201820192020202120222023
Return on Capital Employed xxxxxxxxxxxxxxx10.78 %
Return on Invested Capital xxxxxxxxxxxxxxx7.07 %
Return on Assets xxxxxxxxxxxxxxx3.99 %
Return on Equity xxxxxxxxxxxxxxx10.78 %
Return on Total Capital xxxxxxxxxxxxxxx12.06 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx121.6 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 201820192020202120222023
Short-Term Debt xxxxxxxxxxxxxxx92 M
Long Term Debt xxxxxxxxxxxxxxx1,191 M
Total Debt xxxxxxxxxxxxxxx1,283 M
Goodwill - Gross xxxxxxxxxxxxxxx1,976 M
Cash & Equivalents - Generic xxxxxxxxxxxxxxx212 M
Price To Book Value xxxxxxxxxxxxxxx2.66

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 201820192020202120222023
Capex xxxxxxxxxxxxxxx98.4 M
Capex % of Sales xxxxxxxxxxxxxxx0.80 %
Cost of Goods Sold xxxxxxxxxxxxxxx11,322 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx470 M
Research & Development xxxxxxxxxxxxxxx-
Investments - Total xxxxxxxxxxxxxxx69 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

0.8

No. Of Recommendations

5
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Ord Minnett

xx/xx/xxxx

1

xxxxxxxxxx xx xxxxxxxx xxxx xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Citi

xx/xx/xxxx

3

xxxxxxx xx xxxxxxx xxxx xxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Morgan Stanley

22/02/2024

1

Overweight

$37.00

16.17%

Ebos Group 1H revenue and underlying profit were beats of 3% and 4%, resepectively, against Morgan Stanley's forecasts.

Despite these beats the target falls to $37 from $38. Overweight retained. Industry view In-Line.

FORECAST
Morgan Stanley forecasts a full year FY24 EPS of 161.00 cents.
Morgan Stanley forecasts a full year FY25 EPS of 147.00 cents.

Morgans

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Macquarie

xx/xx/xxxx

1

xxxxxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

1

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Jarden

07/05/2024

2

Upgrade to Overweight from Neutral

-

-

Jarden is upbeat that Ebos Group should be able to re-establish its Australian presence in the PBS following the loss of the Chemist Warehouse contract from FY25 onward.

The broker considers growth will be forthcoming from the Hospital medicines segment, medical consumables, and a new 3PL contract as new facilities are constructed.

In re-casting the earnings outlook for growth in Wholesale, Medical Technoligies and Animal Care, Jarden forecasts a compound 5-year EPS growth rate of circa 7% and around 6% dividend annual growth.

Although more subdued than historically, the analyst expects other growth opportunities to emerge.

The rating is upgraded to Overweight and the target is set at NZ$38 from NZ$37.60.

FORECAST
Jarden forecasts a full year FY24 dividend of 107.00 cents and EPS of 161.70 cents.
Jarden forecasts a full year FY25 dividend of 110.00 cents and EPS of 144.20 cents.
Access Stockbroker Research History >

EBO STOCK CHART

FNArena News on EBO

1
Rudi’s View: How To Invest Allan’s $300k, Part 2

Jul 25 2024 - Rudi's View
2
‘Defensive’ Pharmaceutical Wholesalers In Focus

Jul 18 2024 - Australia
3
Rudi’s View: Rate Cuts, Growth & Small Caps

Jul 18 2024 - Rudi's View
4
Rudi’s View: Gold, Healthcare, Staples & Copper

Jul 11 2024 - Rudi's View
5
Weekly Ratings, Targets, Forecast Changes – 05-07-24

Jul 08 2024 - Weekly Reports

Latest Healthcare services News

1
Building The No 3 Diagnostic Imaging Player

Jun 19 2024 - Small Caps
2
Capitol Health’s Higher Margin Outlook

Mar 13 2024 - Small Caps
3
Treasure Chest: Ramsay Health Care

Oct 26 2023 - Treasure Chest
4
Timing Seems Right For Alcidion Group

Jun 21 2023 - Small Caps
5
No Enthusiasm To Combine ACL & Healius

Mar 21 2023 - Australia
6
Dr Boreham’s Crucible: Alcidion

Dec 13 2022 - Small Caps
7
No Straight Covid-Relief For Ramsay Health Care

Nov 15 2022 - Australia
8
Dr Boreham’s Crucible: Mach7 Technologies

Nov 14 2022 - Small Caps
9
Negative Industry Trends Impact Australian Clinical Labs

Aug 12 2022 - Small Caps
10
Healius Offers Digital Carrot, Base Remains Soft

May 25 2022 - Australia